TP53BP2 is associated with the clinicopathological
characteristics of PE
To explore the clinical significance of TP53BP2 in the
progression of PE, we collected 85 placentas from early-onset
PE pregnancies (<34 weeks of gestation, n=45) and non-PE
pregnancies (n=40). The pathological characteristics of these
pregnancies are presented in Table 1. There was no significant
difference in maternal age or fetal sex between PE pregnancies and
non-PE pregnancies (P>0.05). However, systolic and
diastolic blood pressure, as well as proteinuria, were significantly
increased in PE pregnancies (P<0.0001). Additionally,
there was a significant difference in maternal body mass index (BMI)
between PE pregnancies and non-PE pregnancies (P<0.05).
Moreover, compared with non-PE pregnancies, PE pregnancies were
associated with decreased gestational age at delivery and lower neonatal
birth weight (P<0.05), indicating that these
clinicopathological parameters were in accordance with the diagnostic
criteria. To evaluate the significance of TP53BP2 in placental
dysfunction, we analyzed the correlation between TP53BP2 and LC3B-II and
p62 in placentas. The results revealed a positive association between
TP53BP2 levels and LC3B-II levels in both PE and non-PE pregnancies but
a negative correlation with p62 (Figure 4A, B). Additionally, TP53BP2
levels in placentas were positively correlated with systolic blood
pressure, diastolic blood pressure, and BMI but negatively correlated
with gestational age at delivery and neonatal birth weight (Figure
4C-G ). Furthermore, receiver operating characteristic (ROC) analysis
demonstrated that TP53BP2 had the highest area under the curve (AUC)
value of 0.882 for diagnosing PE pregnancies (Figure 4H). Taken
together, these results suggest that TP53BP2 could serve as a
predictive biomarker associated with the clinicopathological
characteristics of PE pregnancies.